Ribociclib 200mg tablets

  • Medicine name- Kryxana
  • API- Ribociclib
  • Packaging- 21 Tablets
  • Strength- 200 mg
  • Manufactured by- Novartis Ltd.
Get an Enquiry


Ribociclib is a kinase inhibitor used to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. It’s given:

  • With an aromatase inhibitor as the first hormonal therapy.

  • With fulvestrant either as initial hormonal therapy or after progression on prior endocrine therapy in postmenopausal women or men.

Dosage and Side Effects

  • Take Ribociclib tablets orally with or without food, combined with an aromatase inhibitor or fulvestrant.

  • Start with a recommended daily dose of 600 mg (three 200 mg tablets) for 21 consecutive days followed by 7 days off treatment.

  • Adjust or discontinue doses based on individual safety and tolerability.

Common side effects include decreased white blood cells, decreased neutrophils, decreased hemoglobin, infections, nausea, increased liver enzymes, fatigue, decreased platelets, diarrhea, vomiting, headache, and hair loss.

Warning and Precautions

  • Lung and Skin Concerns: Monitor for lung issues or skin reactions. Stop Ribociclib in case of severe symptoms.

  • Heart Health: Regularly check heart function and electrolyte levels. Avoid specific medications known to affect heart rhythm.

  • Liver and Blood Counts: Conduct liver function and blood count tests regularly during treatment.

  • Fetal Risks: Advise females to use contraception as Ribociclib can harm a developing fetus.


What is Ribociclib?

Ribociclib is a medication used in treating advanced or metastatic breast cancer in certain adult patients. It belongs to a class of drugs called kinase inhibitors.

How does Ribociclib work?

Ribociclib functions by inhibiting certain proteins (CDK4/6) involved in the growth of cancer cells, thereby slowing down or stopping the progression of the cancer.

Who can use Ribociclib?

Ribociclib 200 mg is prescribed for adults:

With hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.

In combination with specific hormonal therapies as the initial treatment or after progression on prior endocrine therapy.